Abstract
Histone deacetylases (HDACs) 1 and 2 share a high degree of homology and coexist within the same protein complexes. Despite their close association, each possesses unique functions. We show that the upregulation of HDAC2 in colorectal cancer occurred early at the polyp stage, was more robust and occurred more frequently than HDAC1. Similarly, while the expression of HDACs1 and 2 were increased in cervical dysplasia and invasive carcinoma, HDAC2 expression showed a clear demarcation of high-intensity staining at the transition region of dysplasia compared to HDAC1. Upon HDAC2 knockdown, cells displayed an increased number of cellular extensions reminiscent of cell differentiation. There was also an increase in apoptosis, associated with increased p21Cip1/WAF1 expression that was independent of p53. These results suggest that HDACs, especially HDAC2, are important enzymes involved in the early events of carcinogenesis, making them candidate markers for tumor progression and targets for cancer therapy.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Abbreviations
- HDAC:
-
histone deacetylase
- HAT:
-
histone acetylase
- siRNA:
-
small interfering RNA
- TMA:
-
tissue microarray
References
Wade PA (2001) Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin. Hum. Mol. Genet. 10: 693–698
Strahl BD and Allis CD (2000) The language of covalent histone modifications. Nature 403: 41–45
Ito K, Barnes PJ and Adcock IM (2000) Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12. Mol. Cell. Biol. 20: 6891–6903
Forsberg EC and Bresnick EH (2001) Histone acetylation beyond promoters: long-range acetylation patterns in the chromatin world. Bioessays 23: 820–830
Cress WD and Seto E (2000) Histone deacetylases, transcriptional control, and cancer. J. Cell. Physiol. 184: 1–16
Puri PL, Avantaggiati ML, Balsano C, Sang N, Graessmann A, Giordano A and Levrero M (1997) p300 is required for MyoD-dependent cell cycle arrest and muscle-specific gene transcription. EMBO J. 16: 369–383
Yao TP, Oh SP, Fuchs M, Zhou ND, Ch'ng LE, Newsome D, Bronson RT, Li E, Livingston DM and Eckner R (1998) Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell 93: 361–372
Walker SS, Shen WC, Reese JC, Apone LM and Green MR (1997) Yeast TAF(II)145 required for transcription of G1/S cyclin genes and regulated by the cellular growth state. Cell 90: 607–614
Puri PL, Sartorelli V, Yang XJ, Hamamori Y, Ogryzko VV, Howard BH, Kedes L, Wang JY, Graessmann A, Nakatani Y and Levrero M (1997) Differential roles of p300 and PCAF acetyltransferases in muscle differentiation. Mol. Cell 1: 35–45
Eckner R, Yao TP, Oldread E and Livingston DM (1996) Interaction and functional collaboration of p300/CBP and bHLH proteins in muscle and B-cell differentiation. Genes Dev. 10: 2478–2490
Kawasaki H, Eckner R, Yao TP, Taira K, Chiu R, Livingston DM and Yokoyama KK (1998) Distinct roles of the co-activators p300 and CBP in retinoic-acid-induced F9-cell differentiation. Nature 393: 284–289
Suzuki-Yagawa Y, Guermah M and Roeder RG (1997) The ts13 mutation in the TAF(II)250 subunit (CCG1) of TFIID directly affects transcription of D-type cyclin genes in cells arrested in G1 at the nonpermissive temperature. Mol. Cell. Biol. 17: 3284–3294
Marks P, Rifkind RA, Richon VM, Breslow R, Miller T and Kelly WK (2001) Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 1: 194–202
Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, Fanelli M, Ruthardt M, Ferrara FF, Zamir I, Seiser C, Lazar MA, Minucci S and Pelicci PG (1998) Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 391: 815–818
Lin RJ, Nagy L, Inoue S, Shao W, Miller Jr WH and Evans RM (1998) Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391: 811–814
Luo J, Su F, Chen D, Shiloh A and Gu W (2000) Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 408: 377–381
Juan LJ, Shia WJ, Chen MH, Yang WM, Seto E, Lin YS and Wu CW (2000) Histone deacetylases specifically down-regulate p53-dependent gene activation. J. Biol. Chem. 275: 20436–20443
Murphy M, Ahn J, Walker KK, Hoffman WH, Evans RM, Levine AJ and George DL (1999) Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev. 13: 2490–2501
Brehm A, Miska EA, McCance DJ, Reid JL, Bannister AJ and Kouzarides T (1998) Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature 391: 597–601
Magnaghi-Jaulin L, Groisman R, Naguibneva I, Robin P, Lorain S, Le Villain JP, Troalen F, Trouche D and Harel-Bellan A (1998) Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature 391: 601–605
Luo RX, Postigo AA and Dean DC. (1998) Rb interacts with histone deacetylase to repress transcription. Cell 92: 463–473
Yarden RI and Brody LC (1999) BRCA1 interacts with components of the histone deacetylase complex. Proc. Natl. Acad. Sci. USA 96: 4983–4988
De Ruijter AJ, Van Gennip AH, Caron HN, Kemp S and Van Kuilenburg AB (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 370 (Part 3): 737–749
Johnstone RW (2002) Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 1: 287–299
Yang WM, Inouye C, Zeng Y, Bearss D and Seto E (1996) Transcriptional repression by YY1 is mediated by interaction with a mammalian homolog of the yeast global regulator RPD3. Proc. Natl. Acad. Sci. USA 93: 12845–12850
Taunton J, Hassig CA and Schreiber SL (1996) A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 272: 408–411
Zhang Y, Iratni R, Erdjument-Bromage H, Tempst P and Reinberg D (1997) Histone deacetylases and SAP18, a novel polypeptide, are components of a human Sin3 complex. Cell 89: 357–364
Laherty CD, Yang WM, Sun JM, Davie JR, Seto E and Eisenman RN (1997) Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression. Cell 89: 349–356
Knoepfler PS and Eisenman RN (1999) Sin meets NuRD and other tails of repression. Cell 99: 447–450
Hassig CA, Fleischer TC, Billin AN, Schreiber SL and Ayer DE (1997) Histone deacetylase activity is required for full transcriptional repression by mSin3A. Cell 89: 341–347
Xue Y, Wong J, Moreno GT, Young MK, Cote J and Wang W (1998) NURD, a novel complex with both ATP-dependent chromatin-remodeling and histone deacetylase activities. Mol. Cell 2: 851–861
Zhang Y, Ng HH, Erdjument-Bromage H, Tempst P, Bird A and Reinberg D (1999) Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev. 13: 1924–1935
Zhang D, Salto-Tellez M, Putti TC, Do E and Koay ES (2003) Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod. Pathol. 16: 79–84
Lagger G, O'Carroll D, Rembold M, Khier H, Tischler J, Weitzer G, Schuettengruber B, Hauser C, Brunmeir R, Jenuwein T and Seiser C (2002) Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J. 21: 2672–2681
Wagner M, Brosch G, Zwerschke W, Seto E, Loidl P and Jansen-Durr P (2001) Histone deacetylases in replicative senescence: evidence for a senescence-specific form of HDAC-2. FEBS Lett. 499: 101–106
Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP and Gottlicher M (2004) Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 5: 455–463
Marks PA, Richon VM and Rifkind RA (2000) Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 92: 1210–1216
Kramer OH, Gottlicher M and Heinzel T (2001) Histone deacetylase as a therapeutic target. Trends Endocrinol. Metab. 12: 294–300
Kosugi H, Towatari M, Hatano S, Kitamura K, Kiyoi H, Kinoshita T, Tanimoto M, Murate T, Kawashima K, Saito H and Naoe T (1999) Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy. Leukemia 13: 1316–1324
Weidle UH and Grossmann A (2000) Inhibition of histone deacetylases: a new strategy to target epigenetic modifications for anticancer treatment. Anticancer Res. 20: 1471–1485
Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R, Smyth MJ and Johnstone RW (2001) The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc. Natl. Acad. Sci. USA 98: 10833–10838
Vrana JA, Decker RH, Johnson CR, Wang Z, Jarvis WD, Richon VM, Ehinger M, Fisher PB and Grant S (1999) Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene 18: 7016–7025
Kwon SH, Ahn SH, Kim YK, Bae GU, Yoon JW, Hong S, Lee HY, Lee YW, Lee HW and Han JW (2002) Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells. J. Biol. Chem. 277: 2073–2080
Glick RD, Swendeman SL, Coffey DC, Rifkind RA, Marks PA, Richon VM and La Quaglia MP (1999) Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. Cancer Res. 59: 4392–4399
Finzer P, Kuntzen C, Soto U, zur Hausen H and Rosl F (2001) Inhibitors of histone deacetylase arrest cell cycle and induce apoptosis in cervical carcinoma cells circumventing human papillomavirus oncogene expression. Oncogene 20: 4768–4776
Sandor V, Senderowicz A, Mertins S, Sackett D, Sausville E, Blagosklonny MV and Bates SE (2000) P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br. J. Cancer 83: 817–825
Coqueret O (2003) New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol. 13: 65–70
Heliez C, Baricault L, Barboule N and Valette A (2003) Paclitaxel increases p21 synthesis and accumulation of its AKT-phosphorylated form in the cytoplasm of cancer cells. Oncogene 22: 3260–3268
Detjen KM, Murphy D, Welzel M, Farwig K, Wiedenmann B and Rosewicz S (2003) Downregulation of p21(waf/cip-1) mediates apoptosis of human hepatocellular carcinoma cells in response to interferon-gamma. Exp. Cell Res. 282: 78–89
Tian H, Wittmack EK and Jorgensen TJ (2000) p21WAF1/CIP1 antisense therapy radiosensitizes human colon cancer by converting growth arrest to apoptosis. Cancer Res. 60: 679–684
Mahyar-Roemer M and Roemer K (2001) p21 Waf1/Cip1 can protect human colon carcinoma cells against p53-dependent and p53-independent apoptosis induced by natural chemopreventive and therapeutic agents. Oncogene 20: 3387–3398
Han Z, Wei W, Dunaway S, Darnowski JW, Calabresi P, Sedivy J, Hendrickson EA, Balan KV, Pantazis P and Wyche JH (2002) Role of p21 in apoptosis and senescence of human colon cancer cells treated with camptothecin. J. Biol. Chem. 277: 17154–17160
Suzuki A, Kawano H, Hayashida M, Hayasaki Y, Tsutomi Y and Akahane K (2000) Procaspase 3/p21 complex formation to resist fas-mediated cell death is initiated as a result of the phosphorylation of p21 by protein kinase A. Cell Death Differ. 7: 721–728
Chopin V, Toillon RA, Jouy N and Le Bourhis X (2004) P21(WAF1/CIP1) is dispensable for G1 arrest, but indispensable for apoptosis induced by sodium butyrate in MCF-7 breast cancer cells. Oncogene 23: 21–29
Tsao YP, Huang SJ, Chang JL, Hsieh JT, Pong RC and Chen SL (1999) Adenovirus-mediated p21((WAF1/SDII/CIP1)) gene transfer induces apoptosis of human cervical cancer cell lines. J. Virol. 73: 4983–4990
Shibata MA, Yoshidome K, Shibata E, Jorcyk CL and Green JE (2001) Suppression of mammary carcinoma growth in vitro and in vivo by inducible expression of the Cdk inhibitor p21. Cancer Gene Ther. 8: 23–35
MacDonald RJ, Swift GH, Przybyla AE and Chirgwin JM (1987) Isolation of RNA using guanidinium salts. Methods Enzymol. 152: 219–227
Acknowledgements
This work was supported by grants from Academic Research Fund (R-185-000-039-112) and National Medical Research Council (R-185-000-041-213) of Singapore. The Tissue Microarray work was supported by the Singapore Cancer Syndicate grant (SCS-MN5).
Author information
Authors and Affiliations
Corresponding author
Additional information
Edited by M Piacentini
These authors contributed equally to this work
Rights and permissions
About this article
Cite this article
Huang, B., Laban, M., Leung, CW. et al. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ 12, 395–404 (2005). https://doi.org/10.1038/sj.cdd.4401567
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.cdd.4401567
Keywords
This article is cited by
-
UBE4B interacts with the ITCH E3 ubiquitin ligase to induce Ku70 and c-FLIPL polyubiquitination and enhanced neuroblastoma apoptosis
Cell Death & Disease (2023)
-
Antineoplastic activity of plant-derived compounds mediated through inhibition of histone deacetylase: a review
Amino Acids (2023)
-
In silico profiling of histone deacetylase inhibitory activity of compounds isolated from Cajanus cajan
Beni-Suef University Journal of Basic and Applied Sciences (2022)
-
Roles of HDAC2, eIF5, and eIF6 in Lung Cancer Tumorigenesis
Current Medical Science (2021)
-
Targeted therapy for mTORC1-driven tumours through HDAC inhibition by exploiting innate vulnerability of mTORC1 hyper-activation
British Journal of Cancer (2020)
